Allergic reactions including anaphylaxis after receipt of 1st dose of Pfizer-BioNTech COVID-19 Vaccine
What The Study Did:
This JAMA Insights review provides clinical details of anaphylactic reactions reported to and verified by the Centers for Disease Control and Prevention in the first week of use of the Pfizer-BioNTech COVID-19 vaccine in the United States.
Tom Shimabukuro, M.D., M.P.H., M.B.A., of the CDC in Atlanta, is the corresponding author.
To access the embargoed study:
Visit our For The Media website at this link
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
The full article is linked to this news release.
Embed this link to provide your readers free access to the full-text article
This link will be live at the embargo time
JAMA Network Media Relations